Ticagrelor · Brilinta

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Atherosclerotic Cardiovascular Disease, Acute Ischemic Stroke

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (4)
US
  • Acute Coronary Syndrome or a History of Myocardial Infarction BRILINTA is indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS [see Clinical Studies (14.1) ] .
    Outside this platform's coverage
  • Coronary Artery Disease but No Prior Stroke or Myocardial Infarction BRILINTA is indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events [see Clinical Studies (14.2) ] . While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM).
Product first approved 2011FDA label
JP
  • Treatment of:
Product first approved 2016Outside this platform's coveragePMDA
EU
  • Brilique, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS) or a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event Brilique, co-administered with acetyl salicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction (MI occurred at least one year ago) and a high risk of developing an atherothrombotic event.
Product first approved 2010EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (80)
Acute Ischemic Stroke
NCT06853535 · Sichuan Provincial People's Hospital
2025-05-23 – 2027-12-31 · Acute Ischemic Stroke, Clopidogrel Resistance
What this study did
Atherosclerotic Cardiovascular Disease
NCT07582835 · Cardiocentro Ticino
2026-04-20 – 2028-04 · Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndromes, Antiplatelet Therapy, Single Antiplatelet Therapy, Coagulation Factors
What this study did
NCT05476991 · Assistance Publique - Hôpitaux de Paris
2023-05-17 – 2027-09-01 · Stroke, Stroke, Ischemic, Atherosclerosis, Myocardial Infarction, Coronary Syndrome, TIA, Cardiac Disease, Cerebral Infarction
What this study did
NCT03789916 · Campus Bio-Medico University
2019-01-02 – 2026-12-31 · Coronary Artery Disease
What this study did
NCT05779059 · Collegium Medicum w Bydgoszczy
2023-04-01 – 2024-12-31 · Non ST Segment Elevation Acute Coronary Syndrome, Non-ST-Segment Elevation Myocardial Infarction (NSTEMI), Unstable Angina
What this study did
NCT04718025 · Collegium Medicum w Bydgoszczy
2022-02-07 – 2024-06-30 · STEMI, NSTEMI, Unstable Angina
What this study did
NCT04007055 · Marissa Jarosinski
2019-08-09 – 2024-03-28 · Peripheral Artery Disease, Clopidogrel, Poor Metabolism of, Peripheral Vascular Disease, Artery Disease, Peripheral Arterial Occlusive Disease
What this study did
NCT03357874 · Assistance Publique Hopitaux De Marseille
2018-10-28 – 2023-07-18 · Acute Coronary Syndrome
What this study did
NCT03331484 · Ottawa Heart Institute Research Corporation
2018-11-01 – 2023-07-06 · Atrial Fibrillation, Acute Coronary Syndrome
What this study did
NCT04739384 · Federico II University
2021-04-01 – 2022-06-20 · Acute Coronary Syndrome, STEMI, NSTEMI, Coronary Artery Disease, Myocardial Infarction
What this study did
NCT04069234 · Region Skane
2019-09-15 – 2022-03-31 · Diabetes Mellitus, Microvascular Coronary Artery Disease
What this study did
NCT05474053 · Cairo University
2021-11-13 – 2021-11-28 · Cardiovascular Diseases, Acute Coronary Syndrome
What this study did
NCT03078465 · Nanjing First Hospital, Nanjing Medical University
2017-06-20 – 2021-05-30 · Coronary Artery Disease
What this study did
NCT02617290 · Assistance Publique - Hôpitaux de Paris
2017-01-09 – 2020-09-15 · Coronary Artery Disease, Myocardial Ischemia, Myocardial Infarction, Stent Thrombosis, Cardiovascular Diseases
What this study did
NCT02352402 · J.M. ten Berg
2015-03 – 2020-08 · Coronary Artery Disease, Stable Angina, Acute Coronary Syndrome
What this study did
NCT02944123 · Dong-A University
2016-09 – 2020-06 · Acute Coronary Syndrome
What this study did
NCT01755520 · Deutsches Herzzentrum Muenchen
2013-04-24 – 2018-05-19 · Coronary Artery Disease, Stable Angina, Acute Coronary Syndrome
What this study did
NCT02325466 · Icahn School of Medicine at Mount Sinai
2015-04 – 2018-05-04 · Peripheral Artery Disease, Type 2 Diabetes
What this study did
NCT01813435 · ECRI bv
2013-07-01 – 2018-04-26 · Coronary Artery Disease (CAD)
What this study did
NCT02415803 · First Affiliated Hospital of Harbin Medical University
2014-12 – 2016-12 · Non ST Segment Elevation Acute Coronary Syndrome
What this study did
NCT01812330 · General Hospital of Chinese Armed Police Forces
2013-01 – 2016-07 · Acute Coronary Syndrome
What this study did
NCT01805596 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
2013-04 – 2016-07 · Coronary Artery Disease, Endothelial Function
What this study did
NCT01992523 · David Antoniucci
2013-11 – 2014-04 · Acute Coronary Syndrome, Adverse Reaction to Antiplatelet Agent
What this study did
NCT01626534 · Assistance Publique Hopitaux De Marseille
2012-03 – 2014-02 · Acute Coronary Syndrome
What this study did
NCT01543932 · University of Roma La Sapienza
2012-07 – 2013-12 · Coronary Artery Disease
What this study did
NCT01660373 · Pusan National University Yangsan Hospital
2012-08 – 2013-08 · Non-ST Segment Elevation Acute Coronary Syndrome
What this study did
NCT01757262 · AstraZeneca
2013-01 – 2013-04 · Coronary Heart Disease
What this study did
NCT01360437 · University of Patras
2011-05 – 2011-12 · Coronary Artery Disease, Acute Coronary Syndrome
What this study did
Other / comorbidity
NCT06352632 · The George Institute
2024-09-26 – 2034-09 · Stroke
What this study did
NCT07257198 · Montreal Heart Institute
2026-03-03 – 2031-01-01 · NSTEMI - Non-ST Segment Elevation MI, STEMI (ST Elevation MI), Myocardial Infarction
What this study did
NCT05997693 · Weill Medical College of Cornell University
2024-08-15 – 2031-01 · Chronic Coronary Disease
What this study did
NCT07821008 · University Hospital, Toulouse
2026-11-24 – 2029-12-14 · Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia, Endovascular Procedure
What this study did
NCT05047172 · University of Florida
2022-08-02 – 2027-01-31 · Intracranial Arteriosclerosis, Stroke
What this study did
NCT06316570 · Beijing Tiantan Hospital
2024-04-03 – 2026-01-05 · Ischemic Stroke, Acute
What this study did
NCT06561867 · Kafrelsheikh University
2024-08-30 – 2025-12-20 · Ischemic Stroke
What this study did
NCT06591338 · Kafrelsheikh University
2024-09-01 – 2025-10-10 · Ischemic Stroke
What this study did
NCT06591377 · Kafrelsheikh University
2024-08-10 – 2025-10-01 · Ischemic Stroke
What this study did
NCT06202755 · Kafrelsheikh University
2024-03-30 – 2025-07-12 · Ischemic Stroke
What this study did
NCT06318481 · National Institute of Cardiovascular Diseases, Pakistan
2024-02-19 – 2025-02-20 · Stent Thrombosis, Myocardial Infarction, Acute
What this study did
NCT06196047 · Kafrelsheikh University
2023-12-01 – 2024-12-30 · Ischemic Stroke
What this study did
NCT06591390 · Kafrelsheikh University
2022-02-09 – 2024-10-01 · Ischemic Stroke
What this study did
NCT06591312 · Kafrelsheikh University
2022-05-01 – 2024-09-25 · Ischemic Stroke
What this study did
NCT04286438 · SFJ Pharmaceuticals, Inc.
2020-07-15 – 2024-09-09 · Hemorrhage, Urgent Surgery, Invasive Procedure
What this study did
NCT05553613 · Kafrelsheikh University
2022-10-01 – 2024-01-01 · Ischemic Stroke
What this study did
NCT06120725 · Kafrelsheikh University
2021-09-01 – 2023-11-01 · Ischemic Stroke
What this study did
NCT04738097 · Mazandaran University of Medical Sciences
2021-08-08 – 2023-10-15 · Ischemic Stroke, Transient Ischemic Attack
What this study did
NCT04946929 · RenJi Hospital
2021-07-31 – 2023-03-31 · Hepatic Artery Thrombosis, Liver Transplant; Complications, Pediatric Disease
What this study did
Phase 2/3 (11)
Atherosclerotic Cardiovascular Disease
NCT02701140 · Italo Porto
2016-06 – 2020-11 · Myocardial Ischemia
What this study did
NCT02230527 · The Cleveland Clinic
2014-10 – 2020-05 · Peripheral Arterial Disease
What this study did
NCT03062462 · First Affiliated Hospital of Harbin Medical University
2017-02-10 – 2019-12-31 · Coronary Artery Disease, Clopidogrel, Poor Metabolism of
What this study did
NCT03381742 · First Affiliated Hospital of Harbin Medical University
2017-12-13 – 2019-02-13 · Coronary Artery Disease
What this study did
NCT02110303 · University of Edinburgh
2015-03 – 2018-04 · Coronary Artery Disease
What this study did
NCT02889549 · First Affiliated Hospital of Harbin Medical University
2016-08 – 2017-10 · Coronary Artery Disease
What this study did
NCT02044146 · Ottawa Heart Institute Research Corporation
2014-09 – 2017-06 · Acute Coronary Syndrome, Percutaneous Coronary Intervention
What this study did
NCT01894789 · Ottawa Heart Institute Research Corporation
2013-03 – 2015-03 · Coronary Artery Disease
What this study did
Other / comorbidity
NCT06653348 · Mazandaran University of Medical Sciences
2024-04-01 – 2026-08-01 · Ischemic Stroke, Transient Ischemic Attack
What this study did
NCT02506140 · Beijing Tiantan Hospital
2015-08 – 2018-03 · Stroke, Ischemic Attack, Transient
What this study did
NCT02048228 · Chinese PLA General Hospital
2014-10 – 2016-08 · CLOPIDOGREL, POOR METABOLISM of (Disorder)
What this study did
Phase 2 (31)
Acute Ischemic Stroke
NCT07844603 · University of Alberta
2027-01-01 – 2030-12-31 · Acute Ischemic Stroke
What this study did
Atherosclerotic Cardiovascular Disease
NCT04766437 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2021-02-19 – 2023-03-03 · Non ST Segment Elevation Acute Coronary Syndrome
What this study did
NCT03039205 · University of Sao Paulo
2017-11-07 – 2019-12-19 · Platelet Aggregation, Adenosine, Coronary Artery Disease, Kidney Dysfunction, Antiplatelet Therapy
What this study did
NCT02925923 · University of Alabama at Birmingham
2016-11-01 – 2018-12-01 · Acute Coronary Syndrome, Angina, Unstable
What this study did
NCT02071212 · Hellenic Cardiovascular Research Society
2014-02 – 2018-06 · Coronary Artery Disease
What this study did
NCT02319941 · Seung-Jung Park
2015-05-20 – 2017-03-10 · Acute Coronary Syndrome
What this study did
NCT02519608 · University Hospital of Ferrara
2015-09 – 2017-01 · Coronary Artery Disease, Chronic Obstructive Pulmonary Disease
What this study did
NCT02293395 · Janssen Research & Development, LLC
2015-04-20 – 2016-10-14 · Acute Coronary Syndrome
What this study did
NCT02227368 · AstraZeneca
2014-10-20 – 2016-05-23 · Peripheral Artery Disease (PAD)
What this study did
NCT01919723 · University of Alabama at Birmingham
2014-02 – 2015-12 · Acute Coronary Syndrome
What this study did
NCT01898442 · University of Florida
2013-09 – 2014-06 · Coronary Artery Disease
What this study did
NCT02120092 · Medical University of Vienna
2010-10 – 2013-12 · Acute Coronary Syndrome
What this study did
NCT01766466 · The Medicines Company
2013-01 – 2013-02 · Coronary Artery Disease
What this study did
NCT01118325 · AstraZeneca
2010-04 – 2011-03 · Stable Coronary Artery Disease
What this study did
NCT00642811 · AstraZeneca
2008-05 – 2009-03 · Stable Coronary Artery Disease
What this study did
NCT00528411 · AstraZeneca
2007-10 – 2009-03 · Coronary Artery Disease
What this study did
Other / comorbidity
NCT07911124 · University of Arkansas
2026-11 – 2031-07 · Chronic Kidney Disease (CKD)
What this study did
NCT05149560 · Vastra Gotaland Region
2021-12-14 – 2025-06-26 · Acute Myocardial Infarction
What this study did
NCT02677545 · University Hospital, Basel, Switzerland
2016-12 – 2022-04-28 · Carotid Artery Stenosis
What this study did
NCT04122170 · SFJ Pharmaceuticals, Inc.
2019-09-24 – 2021-09-01 · Healthy
What this study did
NCT02285751 · Medical University of Vienna
2012-11 – 2020-08 · Critical Illness
What this study did
NCT03145194 · Papworth Hospital NHS Foundation Trust
2017-01-30 – 2019-11-30 · ST Elevation Myocardial Infarction
What this study did
NCT03928353 · SFJ Pharmaceuticals, Inc.
2019-04-16 – 2019-10-09 · Healthy
What this study did
NCT02507323 · Yochai Birnbaum
2016-02 – 2017-11 · Cardiovascular Disease
What this study did
NCT02070653 · Uppsala University
2014-03 – 2017-07 · Abdominal Aortic Aneurysm
What this study did
NCT02214121 · AstraZeneca
2014-09-11 – 2017-02-27 · Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease
What this study did
NCT01738100 · Hyeon-Cheol Gwon
2012-09 – 2016-12 · ST-Segment Elevation Myocardial Infarction
What this study did
NCT02482298 · AstraZeneca
2015-07-09 – 2016-11-16 · Sickle Cell Disease
What this study did
NCT01998399 · Gordon Bernard
2014-08 – 2015-12 · Community Acquired Pneumonia, Severe
What this study did
NCT02435563 · University Hospital, Geneva
2014-08 – 2015-04 · Healthy
What this study did
Phase 1/2 (4)
Atherosclerotic Cardiovascular Disease
NCT04206176 · The University of The West Indies
2019-10-01 – 2020-03-31 · Platelet Dysfunction Due to Drugs
What this study did
NCT02091921 · University of Southern California
2014-02-16 – 2016-11-30 · Critical Limb Ischemia
What this study did
Other / comorbidity
NCT05831462 · Assiut University
2023-06-01 – 2024-05-01 · Ticagrelor
What this study did
NCT02335099 · University of Virginia
2014-12 – 2019-06 · End Stage Renal Disease, Vascular Access Patency
What this study did
Phase 1 (37)
Atherosclerotic Cardiovascular Disease
NCT06584812 · Tianjin Institute of Pharmaceutical Research Co., Ltd
2024-09-09 – 2024-12-17 · Acute Coronary Syndrome, Ischemic Stroke
What this study did
NCT01690884 · Vanderbilt University
2012-08 – 2017-01 · Coronary Artery Disease
What this study did
NCT02080858 · Medical University of Vienna
2014-05 – 2015-02 · Atrial Fibrillation, Acute Coronary Syndrome
What this study did
NCT00738842 · AstraZeneca
2008-05 – 2008-07 · Gout, Coronary Artery Disease
What this study did
Other / comorbidity
NCT07438886 · Advenchen Laboratories Nanjing Ltd.
2026-03-02 – 2027-03-31 · Healthy Volunteer
What this study did
NCT07444164 · Laboratorios Silanes S.A. de C.V.
2025-01-13 – 2025-02-05 · Healthy
What this study did
NCT06671470 · Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
2024-08-22 – 2024-10-15 · Insomnia
What this study did
NCT06554821 · AstraZeneca
2024-08-05 – 2024-10-08 · Healthy Participants
What this study did
NCT06233266 · Bio-innova Co., Ltd
2024-06-18 – 2024-08-02 · Healthy Subjects
What this study did
NCT05373277 · Helsinki University Central Hospital
2022-05-11 – 2022-12-31 · Pharmacokinetics
What this study did
NCT05162131 · SFJ Pharmaceuticals, Inc.
2021-12-25 – 2022-12-30 · Healthy
What this study did
NCT04091074 · Assiut University
2022-01-01 – 2022-12-01 · Carotid Stenosis
What this study did
NCT04945616 · Jiangsu HengRui Medicine Co., Ltd.
2021-07-13 – 2022-06-15 · Thrombosis
What this study did
NCT04588727 · AstraZeneca
2020-10-15 – 2022-01-19 · Cardiovascular Disease
What this study did
NCT03430661 · Viatris Innovation GmbH
2018-01-24 – 2019-05-29 · Healthy
What this study did
NCT03492931 · AstraZeneca
2018-03-28 – 2019-05-07 · Sickle Cell Disease
What this study did
NCT03492385 · SFJ Pharmaceuticals, Inc.
2018-04-03 – 2018-09-18 · Healthy
What this study did
NCT03441412 · Vastra Gotaland Region
2018-02-28 – 2018-03-28 · Healthy Volunteers
What this study did
NCT03126695 · AstraZeneca
2017-05-12 – 2017-07-24 · Sickle Cell Disease
What this study did
NCT05278637 · Duke University
2013-11-01 – 2016-12-05 · Platelet Aggregation Inhibitors, Aspirin, Ticagrelor, RNA
What this study did
NCT03092076 · Guangdong Provincial People's Hospital
2015-05-20 – 2016-06-16 · Healthy
What this study did
NCT01883869 · University of Kentucky
2013-06 – 2016-06 · Pneumonia, Community Acquired Pneumonia, Hospital Acquired Pneumonia, Acute Lung Injury
What this study did
NCT02022748 · AstraZeneca
2013-12-29 – 2016-05-09 · Kidney Failure, Chronic
What this study did
NCT02436577 · AstraZeneca
2015-06 – 2015-08 · Bioequivalence, Healthy Japanese Subjects, Pharmacokinetics
What this study did
NCT02400333 · AstraZeneca
2015-06 – 2015-07 · Bioavailability, Healthy Subjects
What this study did
NCT01744288 · AstraZeneca
2012-12 – 2014-04 · Inhibition on Platelet Aggregation
What this study did
NCT01887626 · AstraZeneca
2013-07 – 2013-09 · Bioavailability Heathy Volunteers
What this study did
NCT01876797 · Asan Medical Center
2013-07 – 2013-08 · Healthy
What this study did
NCT01734772 · Boehringer Ingelheim
2012-11 – 2013-06 · Healthy
What this study did
NCT01588626 · AstraZeneca
2012-05 – 2012-06 · Healthy
What this study did
NCT01504906 · AstraZeneca
2012-01 – 2012-06 · Healthy
What this study did
NCT01595854 · Boehringer Ingelheim
2012-05 – 2012-06 · Healthy
What this study did
NCT01350921 · AstraZeneca
2011-05 – 2012-03 · Drug Drug Interaction
What this study did
NCT01226602 · AstraZeneca
2010-12 – 2011-04 · Blood Flow Speed, Coronary Flow Velocity
What this study did
NCT00685906 · AstraZeneca
2008-04 – 2008-10 · Healthy
What this study did
NCT00733265 · AstraZeneca
2007-02 – 2008-09 · Renal Impairment
What this study did
NCT00721448 · AstraZeneca
2008-06 – 2008-08 · Pharmacokinetics
What this study did
Phase 4 (186)
Atherosclerotic Cardiovascular Disease
NCT03560310 · Vastra Gotaland Region
2018-06-29 – 2035-02-15 · Acute Coronary Syndrome
What this study did
NCT06451198 · Shanghai Zhongshan Hospital
2025-05-19 – 2028-12-31 · Coronary Artery Disease, Antiplatelet Drugs
What this study did
NCT07080684 · University of Messina
2026-11-01 – 2028-09 · Chronic Coronary Syndrome
What this study did
NCT06228456 · University of Florida
2024-04-01 – 2027-04-30 · Coronary Artery Disease
What this study did
NCT04937699 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2023-03-28 – 2026-12-31 · Acute Coronary Syndrome, Percutaneous Coronary Intervention
What this study did
NCT04240834 · Fu Wai Hospital, Beijing, China
2021-02-01 – 2026-12 · Acute Coronary Syndrome, Interventional Cardiology
What this study did
NCT04695106 · Medical University of Gdansk
2021-10-25 – 2026-08-31 · Atrial Fibrillation, Antithrombotic Therapy, Acute Coronary Syndrome, Percutaneous Coronary Interventions
What this study did
NCT05681702 · University of Florida
2023-02-15 – 2026-08-05 · Coronary Artery Disease
What this study did
NCT04981041 · Ludwig-Maximilians - University of Munich
2021-12-16 – 2026-05-30 · Acute Coronary Syndrome, Atrial Fibrillation
What this study did
NCT06509893 · Shiraz University of Medical Sciences
2024-08-01 – 2026-05-01 · Coronary Artery Disease
What this study did
NCT03729401 · Ottawa Heart Institute Research Corporation
2019-08-22 – 2026-02-26 · Coronary Artery Disease, Myocardial Infarction
What this study did
NCT06088433 · Fu Wai Hospital, Beijing, China
2023-11-15 – 2025-11-30 · Coronary Heart Disease
What this study did
NCT05380063 · China National Center for Cardiovascular Diseases
2023-02-14 – 2025-07-10 · Coronary Artery Disease, Coronary Artery Bypass Grafting, Dual Antiplatelet Therapy, Bleeding, Myocardial Infarction, Myocardial Ischemia, Angina Pectoris
What this study did
NCT05767723 · Hospital Israelita Albert Einstein
2023-02-06 – 2025-06-30 · Acute Coronary Syndrome
What this study did
NCT04483583 · University of Florida
2020-12-08 – 2025-01-07 · Coronary Artery Disease
What this study did
NCT04255602 · Shanghai Tong Ren Hospital
2020-02-19 – 2024-12-31 · Acute Coronary Syndrome, Coronary Stent Implantation
What this study did
NCT07622056 · Kaohsiung Veterans General Hospital.
2024-01-03 – 2024-12-31 · Coronary Heart Disease
What this study did
NCT04307485 · Shanghai Tong Ren Hospital
2020-03-10 – 2024-07 · Senior Acute Coronary Syndrome Patients After PCI
What this study did
NCT04484259 · University of Florida
2021-03-31 – 2024-06-15 · Diabetes Mellitus, Type 2, Coronary Artery Disease
What this study did
NCT04307511 · Shanghai Tong Ren Hospital
2020-04-20 – 2024-05-31 · Acute Coronary Syndrome Patients With Diabetes After PCI
What this study did
NCT05166538 · Yonsei University
2022-02-01 – 2023-12 · Multi Vessel Coronary Artery Disease
What this study did
NCT04688723 · Zuyderland Medisch Centrum
2020-12-23 – 2023-07-01 · Coronary Artery Disease, Myocardial Ischemia, Myocardial Infarction, Atrial Fibrillation
What this study did
NCT02494895 · Yonsei University
2015-08-01 – 2023-05 · Acute Coronary Syndrome
What this study did
NCT04057300 · McGill University Health Centre/Research Institute of the McGill University Health Centre
2018-10-01 – 2023-04-01 · Acute Coronary Syndrome
What this study did
NCT03869268 · Sheffield Teaching Hospitals NHS Foundation Trust
2019-04-24 – 2023-02-09 · Acute Coronary Syndrome
What this study did
NCT05516784 · Universiti Sains Malaysia
2019-09-01 – 2022-08-22 · Coronary Artery Disease (CAD)
What this study did
NCT04060914 · Beijing Anzhen Hospital
2019-08-30 – 2021-12-30 · Antiplatelet Therapy, Coronary Artery Disease, Percutaneous Coronary Intervention
What this study did
NCT05247385 · University of Sao Paulo
2017-03-20 – 2021-12-20 · Coronary Artery Disease
What this study did
NCT03273075 · Medical University of Vienna
2017-09 – 2021-12 · Cardiopulmonary Arrest With Successful Resuscitation, ACS - Acute Coronary Syndrome, Hypothermia, Induced
What this study did
NCT04023630 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2019-10-01 – 2021-09-30 · Atrial Fibrillation, Acute Coronary Syndromes
What this study did
NCT04567290 · Centro Hospitalario La Concepcion
2020-10-07 – 2021-09-30 · Acute Coronary Syndrome
What this study did
NCT01944800 · Deutsches Herzzentrum Muenchen
2013-09-15 – 2021-09 · Acute Coronary Syndrome (ACS)
What this study did
NCT04116931 · The First Affiliated Hospital with Nanjing Medical University
2020-06-22 – 2021-06-30 · Acute Coronary Syndrome (ACS)
What this study did
NCT03381755 · First Affiliated Hospital of Harbin Medical University
2018-01-01 – 2020-12-14 · Acute Coronary Syndrome
What this study did
NCT04001894 · First Affiliated Hospital of Harbin Medical University
2019-07-02 – 2020-12-09 · Platelet Reactivity
What this study did
NCT01742117 · Mayo Clinic
2013-05 – 2020-10-31 · Coronary Artery Disease, Acute Coronary Syndrome, Stenosis
What this study did
NCT03437044 · University of Florida
2018-03-14 – 2020-06-27 · Diabetes Mellitus, Type 2, Coronary Artery Disease
What this study did
NCT02539160 · University of Florida
2016-02 – 2020-06-17 · Coronary Artery Disease, Diabetes Mellitus
What this study did
NCT03150667 · North Texas Veterans Healthcare System
2017-04-10 – 2020-04-30 · Chronic Kidney Diseases, Acute Coronary Syndrome
What this study did
NCT04369534 · University of Zagreb
2015-12-01 – 2019-12-01 · Acute Coronary Syndrome, STEMI, NSTEMI - Non-ST Segment Elevation MI, PLATELET AGGREGATION, INDIVIDUALIZED THERAPY
What this study did
NCT02341729 · University Hospital, Ghent
2015-03 – 2019-12 · Acute Coronary Syndrome
What this study did
NCT03182855 · University of Aarhus
2018-09-01 – 2019-08-01 · Acute Coronary Syndrome, Myocardial Infarction, STEMI - ST Elevation Myocardial Infarction
What this study did
NCT02065479 · University of Florida
2014-03 – 2019-04-22 · Coronary Artery Disease
What this study did
NCT03489863 · University of Florida
2018-05-30 – 2019-03-20 · Coronary Artery Disease
What this study did
NCT02206815 · Genshan Ma
2014-09-19 – 2019-02-20 · Atrial Fibrillation, Coronary Artery Disease
What this study did
NCT03387826 · Attikon Hospital
2018-01-11 – 2019-01-31 · Myocardial Infarction, Diabetes Mellitus, Coronary Artery Disease, Renal Disease
What this study did
NCT03881943 · The University of Hong Kong
2017-01 – 2018-12-21 · Acute Coronary Syndrome
What this study did
NCT02748330 · Peking Union Medical College Hospital
2016-06 – 2018-12 · Coronary Artery Disease, Diabetes Mellitus, Type 2
What this study did
NCT02094963 · Seung-Jung Park
2014-07-05 – 2018-11-01 · Acute Coronary Syndrome, Myocardial Ischemia, Heart Diseases, Cardiovascular Diseases, Angina Pectoris
What this study did
Early phase / not applicable (40)
Atherosclerotic Cardiovascular Disease
NCT06714526 · Sunnybrook Health Sciences Centre
2025-10-07 – 2027-08 · Intracranial Atherosclerosis
What this study did
NCT07613840 · Massachusetts General Hospital
2025-04-29 – 2027-06-30 · Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis), Platelet Aggregation Inhibitors, Thromboelastography (TEG), PRU(Platelet Reactivity Unit)
What this study did
NCT06981390 · Kexiang Liu, MD
2026-05-01 – 2027-03-20 · Coronary Artery Disease, Coronary Artery Bypass Grafting, Saphenous Vein, Dual Antiplatelet Therapy
What this study did
NCT04971356 · Xijing Hospital
2021-11-01 – 2026-12-01 · Antiplatelet Drug, Acute Coronary Syndrome, Angioplasty, Balloon
What this study did
NCT07597239 · Massachusetts General Hospital
2023-01-01 – 2026-12 · Thrombosis, Arterial Occlusive Diseases, Thromboelastography (TEG), Peripheral Arterial Disease(PAD), Stent Thrombosis, Platelet Inhibition, PRU(Platelet Reactivity Unit)
What this study did
NCT07268859 · Acibadem University
2025-03-15 – 2026-01-30 · Acute Coronary Syndromes, Ticagrelor, Dyspnea
What this study did
NCT05015699 · Sino Medical Sciences Technology Inc.
2021-09 – 2025-07 · Coronary Artery Disease
What this study did
NCT03797651 · Yonsei University
2019-04-24 – 2025-04-04 · Coronary Artery Disease, Acute Coronary Syndrome
What this study did
NCT04338919 · Fujian Medical University
2020-04-14 – 2023-04-01 · Acute Coronary Syndrome, Percutaneous Coronary Intervention
What this study did
NCT04744571 · Beijing Anzhen Hospital
2021-02 – 2023-01 · Coronary Artery Disease, Coronary Occlusion, Percutaneous Coronary Intervention, Chronic Total Occlusion of Coronary Artery, Drug-Eluting Stents
What this study did
NCT02668562 · Ottawa Heart Institute Research Corporation
2016-02 – 2022-03-09 · Acute Coronary Syndrome
What this study did
NCT04625764 · CytoSorbents Europe GmbH
2021-02-23 – 2021-12-14 · Acute Coronary Syndrome
What this study did
NCT01701453 · Samsung Medical Center
2012-08 – 2019-11 · Acute Coronary Syndrome
What this study did
NCT02762864 · Chang Gung Memorial Hospital
2016-05 – 2019-04 · Peripheral Artery Disease
What this study did
NCT02428725 · Assistance Publique Hopitaux De Marseille
2015-04 – 2018-04 · Acute Coronary Syndrome
What this study did
NCT03577652 · Shenyang Northern Hospital
2017-07-10 – 2018-01-10 · Coronary Artery Disease, Ticagrelor
What this study did
NCT02618733 · Dong-A University
2014-12 – 2016-12-31 · Acute Coronary Syndrome
What this study did
NCT02244710 · Fundación Investigación Sanitaria en León
2015-03 – 2016-09 · Acute Coronary Syndrome (ACS)
What this study did
NCT02699008 · Wuhan Asia Heart Hospital
2014-01 – 2015-10 · Acute Coronary Syndrome
What this study did
NCT02081443 · University of Florida
2014-04 – 2015-10 · Coronary Artery Disease
What this study did
NCT02016170 · University of Florida
2014-03 – 2015-10 · Coronary Artery Disease, Acute Coronary Syndrome
What this study did
NCT01852214 · University of Florida
2013-02 – 2015-08 · Diabetes Mellitus, Coronary Artery Disease
What this study did
NCT01852175 · University of Florida
2012-01 – 2014-07 · Coronary Artery Disease
What this study did
NCT01731041 · University of Florida
2013-01 – 2014-06 · Coronary Artery Disease
What this study did
NCT01795820 · University Magna Graecia
2012-11 – 2013-01 · Acute Coronary Syndrome
What this study did
Other / comorbidity
NCT07822620 · University Hospital, Rouen
2026-11 – 2030-03 · Cardiac Surgery
What this study did
NCT05986968 · Radboud University Medical Center
2023-07-06 – 2026-12-12 · ST Elevation Myocardial Infarction
What this study did
NCT06301776 · The Fourth Affiliated Hospital of China Medical University
2023-12-05 – 2026-06-30 · Brain Disease, Vertebral Artery Stenosis
What this study did
NCT06015477 · The First Affiliated Hospital with Nanjing Medical University
2024-01-01 – 2025-07-01 · Intracranial Aneurysm, Stent Complication
What this study did
NCT04976530 · CytoSorbents, Inc
2021-08-31 – 2023-08-07 · Hemorrhage, Surgical, Blood Loss, Surgical, Blood Loss, Postoperative, Hemorrhage Postoperative
What this study did
NCT05858918 · Shiraz University of Medical Sciences
2022-10-01 – 2023-03-01 · Stable Chronic Angina
What this study did
NCT04131959 · CytoSorbents, Inc
2019-10-29 – 2021-05-04 · Emergent Cardiothoracic Surgery, Bleeding, Drug Removal
What this study did
NCT03435133 · AORTICA Group
2015-11-23 – 2018-12-31 · ST Elevation Myocardial Infarction
What this study did
NCT02531165 · Centre Hospitalier Universitaire Vaudois
2015-09 – 2018-02-06 · Acute Myocardial Infarction
What this study did
NCT03104062 · University of Sao Paulo General Hospital
2016-10-01 – 2018-02-01 · Coronary Microvascular Disease, Ticagrelor, Thrombolysis, Microbubble Contrasted Echocardiography
What this study did
NCT03005704 · Hamilton Health Sciences Corporation
2017-01 – 2018-01 · Ticagrelor, Aspirin, Platelet Dysfunction Due to Drugs, Transfusion
What this study did
NCT02101437 · Taipei City Hospital
2014-01 – 2017-11-01 · PRU, miRNA
What this study did
NCT02798874 · Chinese PLA General Hospital
2016-05 – 2016-12 · Cardiovascular Diseases
What this study did
NCT02612480 · Radboud University Medical Center
2015-10 – 2015-12 · Endotoxemia
What this study did
Used as active comparator (14)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2 (1)
Other / comorbidity
NCT03487406 · Newcastle-upon-Tyne Hospitals NHS Trust
2015-09 – 2017-11 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
Phase 1 (2)
Atherosclerotic Cardiovascular Disease
NCT01526577 · LG Life Sciences
2012-03 – 2013-08 · Acute Coronary Syndrome
What this study did
Other / comorbidity
NCT04941196 · University of Karachi
2020-10-16 – 2020-11-25 · Healthy Individuals
What this study did
Phase 4 (11)
Atherosclerotic Cardiovascular Disease
NCT06691191 · University of Florida
2025-01-08 – 2027-04-30 · Coronary Artery Disease
What this study did
NCT05183178 · Vastra Gotaland Region
2022-02-01 – 2025-08-31 · Acute Coronary Syndrome
What this study did
NCT04734353 · Gyeongsang National University Hospital
2020-01-15 – 2022-06-15 · Coronary Artery Disease
What this study did
NCT04006288 · University of Florida
2019-09-06 – 2022-05-16 · Coronary Artery Disease
What this study did
NCT03775746 · East and North Hertfordshire NHS Trust
2019-01-08 – 2021-12 · Acute Coronary Syndrome
What this study did
NCT02317198 · St. Antonius Hospital
2013-06 – 2019-11 · Non-ST-elevation Acute Coronary Syndrome, Unstable Angina, Non-ST-elevation Myocardial Infarction
What this study did
NCT02287909 · University of Florida
2014-12 – 2018-03 · Coronary Artery Disease
What this study did
NCT01587651 · Daiichi Sankyo
2012-03 – 2013-02 · Coronary Artery Disease
What this study did
Other / comorbidity
NCT06756945 · Beijing Anzhen Hospital
2025-01 – 2027-12 · ST-elevation Myocardial Infarction (STEMI)
What this study did
NCT03551964 · Faculty Hospital Kralovske Vinohrady
2018-08-01 – 2025-04-01 · Acute Myocardial Infarction, Cardiogenic Shock
What this study did
NCT02018055 · The Catholic University of Korea
2014-02-14 – 2021-01-21 · Acute Myocardial Infarction
What this study did
Appears in other studies (8)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 4 (6)
Atherosclerotic Cardiovascular Disease
NCT02627521 · Unity Health Toronto
2015-07 – 2017-08 · Coronary Artery Disease
What this study did
NCT02403830 · University of Florida
2015-08 – 2016-05 · Coronary Artery Disease
What this study did
Other / comorbidity
NCT06588595 · University of Florida
2024-11-01 – 2028-02-28 · Coronary Arterial Disease (CAD)
What this study did
NCT03224923 · Ottawa Heart Institute Research Corporation
2017-08-18 – 2018-09-30 · Stable Coronary Syndrome, Percutaneous Coronary Intervention, Antiplatelet Therapy, Ticagrelor
What this study did
NCT02943369 · Attikon Hospital
2017-07-28 – 2017-12-26 · STEMI
What this study did
NCT02910778 · Medical University of Vienna
2016-10 – 2017-03 · Ischemia
What this study did
Early phase / not applicable (2)
Atherosclerotic Cardiovascular Disease
NCT05209412 · Xijing Hospital
2022-02-01 – 2025-02-01 · De Novo Stenosis, Coronary Artery Disease, Percutaneous Coronary Intervention
What this study did
Other / comorbidity
NCT05885932 · Xuanwu Hospital, Beijing
2023-08-25 – 2028-09-01 · Ischemic Stroke, Vertebral Artery Stenosis
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Atherosclerotic Cardiovascular Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ticagrelor (Brilinta): this drugApprovedSmall moleculeP2Y12 receptorPartial signalFeatured results are non-efficacy only in this race
Alirocumab (Praluent)ApprovedMonoclonal antibodyPCSK9Weak signal
NCT03510884: DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand (Baseline, Week 24): DB Period: Alirocumab Q2W -33.6 percent change (Standard Error 3.4) | Db Period: Alirocumab Q4W -38.2 percent change (Standard Error 4) vs DB Period: Placebo Q2W 9.7 percent change (Standard Error 4.3) | Db Period: Placebo Q4W -4.4 percent change (Standard Error 3.7)
NCT01709500: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--to--Treat (ITT) Analysis (From Baseline to Week 52): Alirocumab 75 mg/up to 150 mg -48.7 percent change (Standard Error 1.9) vs Placebo 2.8 percent change (Standard Error 2.8)
Bempedoic Acid (Nexletol)ApprovedSmall moleculeATP citrate lyasePartial signal
NCT02991118: Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) (Baseline; Week 12): Bempedoic Acid -15.07 percent change (Standard Error 1.073) vs Placebo 2.35 percent change (Standard Error 1.446)
NCT02988115: Percent Change From Baseline (PCFB) in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 (Baseline; Week 12): Bempedoic Acid -22.58% (Standard Error 1.29) vs Placebo -1.17% (Standard Error 1.421)
Bempedoic Acid / Ezetimibe (Nexlizet)ApprovedSmall moleculeATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe)Partial signal
NCT03337308: Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) (Baseline; Week 12): Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC -36.2% (Standard Error 2.56) vs Bempedoic Acid 180 mg -17.2% (Standard Error 2.52) vs Ezetimibe 10 mg -23.2% (Standard Error 2.18) vs Placebo 1.8% (Standard Error 3.49)
Cangrelor (Kengreal)ApprovedSmall moleculeP2Y12 receptorPartial signal
NCT00385138: Death, MI or ischemia-driven revascularization at 48 h: 7.0% cangrelor (185/2654) vs 8.0% placebo (210/2641); OR 0.87, 95% CI 0.71 to 1.07; P=0.17. Both arms received clopidogrel 600 mg (CHAMPION PLATFORM, NEJM 2009). missed
Colchicine (cardiovascular) (Lodoco)ApprovedSmall moleculeMicrotubule/inflammasome (tubulin)not yet gradedNo reviewed efficacy summary in this indication
Dulaglutide (Trulicity)ApprovedPeptideGLP-1 receptorReliable signal
NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
Evolocumab (Repatha)ApprovedMonoclonal antibodyPCSK9Partial signal
NCT02392559: Percent Change From Baseline to Week 24 in LDL-C (Baseline, Week 24): EvoMab 420 mg QM -44.53 percent change (Standard Error 2.17) vs Placebo -6.23 percent change (Standard Error 3.08)
NCT02207634: Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score (Assessments were conducted at Baseline and at weeks 24, 48, 96, 144 and end of study visit (median time on study was 19.4 months).): Evolocumab 0.1134 Z score (95% CI 0.0449 to 0.182) vs Placebo 0.1206 Z score (95% CI 0.0535 to 0.1877)
Ezetimibe / Simvastatin (Vytorin)ApprovedSmall moleculeHMG-CoA reductase / NPC1L1Reliable signal
NCT00202878: Time to First Occurrence of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event) (Up to approximately 9 years): Ezetimibe/Simvastatin 32.72% (95% CI 31.63 to 33.85) vs Simvastatin 34.67% (95% CI 33.56 to 35.81)
NCT00110435: Percent reduction in LDL-C from baseline at 6 weeks: ezetimibe/simvastatin 10/20mg -53.6% vs atorvastatin 10mg -38.3% (P<.001) and vs atorvastatin 20mg -44.6% (P<.001); ezetimibe/simvastatin 10/40mg -57.6% vs atorvastatin 40mg -50.9% (P<.001). Primary endpoint (percent change from baseline in LDL-C) significantly favored ezetimibe/simvastatin at both dose comparisons.
Icosapent Ethyl (Vascepa)ApprovedSmall moleculeOmega-3 fatty acid (EPA)Reliable signal
NCT01492361: Composite of CV Death, Nonfatal MI (Including Silent MI), Nonfatal Stroke, Coronary Revascularization, or Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization. (Total follow-up time of up to approximately 6 years.): AMR101 705/4089 vs Placebo 901/4090
Liraglutide (Victoza)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
RosuvastatinApprovedSmall moleculeHMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT04560998: Maximum walking distance at Week 52: semaglutide 1 mg superior to placebo by 13% (estimated treatment ratio 1.13; 95% CI 1.06-1.21; p=0.0004); median treatment difference 26.4 meters (~87 feet) on a 12% incline treadmill
NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9%
Semaglutide (Rybelsus)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Semaglutide (Wegovy)ApprovedPeptideGLP-1 receptorReliable signal
NCT03574597: Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801
Tirzepatide (Mounjaro)ApprovedPeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
AG2304Phase 3Small moleculeHMG-CoA reductase / NPC1L1Partial signalNo reviewed efficacy summary in this indication
AlprostadilPhase 3Small moleculeProstaglandin E1 receptornot yet graded
NCT01263925: ClinicalTrials.gov results section for NCT01263925 ('Intravenous Prostaglandin E1 Treatment in Outpatients With Intermittent Claudication', UCB Pharma, Phase 3, enrollment 561/541 FAS, completed April 2011 -- matches this record exactly). Primary outcome: pain-free walking-distance ratio vs active comparator (pentoxifylline) across three periods; both treatments produced similar improvements with no clear superiority of either. phase 3 result · pivotal pending
Amlodipine / Valsartan / Atorvastatin (CJ-30061)Phase 3Small moleculeAngiotensin II receptor / Calcium channel / HMG-CoA reductasePartial signalNo reviewed efficacy summary in this indication
Beperminogene Perplasmid (HGF Plasmid) (Collategene)Phase 3Gene therapy / editingHGF (hepatocyte growth factor), Hepatocyte growth factor (HGF)not yet gradedNo reviewed efficacy summary in this indication
Cilostazol / Rosuvastatin (UI022 / UI023)Phase 3Small moleculePDE3 (phosphodiesterase 3) and HMG-CoA reductaseReliable signal
NCT07600385: KPAQ summary score change (FAS, n=257): test group 15.41 points (SD 14.18) vs control group 10.27 points (SD 14.70); between-group difference 5.14 points (P=0.004), test group superior.
DalcetrapibPhase 3Small moleculeCETPPartial signal
NCT00658515: Primary composite cardiovascular endpoint, dalcetrapib vs placebo: hazard ratio 1.04 (95% CI 0.93 to 1.16), P=0.52; trial stopped for futility (NEJM 2012). missed
NCT01059682: Nominal Change From Baseline to Study End in Coronary Percent Atheroma Volume (PAV) of the Target Coronary Artery Assessed by IVUS. (24 months): Dalcetrapib 0.6% (Standard Deviation 3.69) vs Placebo 0.5% (Standard Deviation 2.01)
Dapagliflozin (Farxiga / Forxiga)Phase 3Small moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
DWC202206 + DWC202207Phase 3Small molecule—Partial signalNo reviewed efficacy summary in this indication
EbronucimabPhase 3Monoclonal antibodyPCSK9Partial signal
NCT05255094: LDL-C percentage change from baseline to week 12 vs placebo: 450 mg Q4W -59.13 percentage points (95% CI -64.10 to -54.15, adjusted p<0.0001); 150 mg Q2W -60.43 percentage points (95% CI -65.45 to -55.416, adjusted p<0.0001).
Enlicitide (Lipfendra)Phase 3PeptidePCSK9Reliable signal
NCT05952856: Week 24 LDL-C mean percent change: -57.1% with enlicitide vs 3.0% with placebo; difference -55.8 percentage points (95% CI -60.9 to -50.7; p<0.001).
NCT05952869: Mean Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 (Baseline and Week 24): Enlicitide Decanoate -58.2% (Standard Deviation 28) vs Placebo 2.6% (Standard Deviation 23.6)
Ezetimibe (Zetia)Phase 3Small moleculeDietary Cholesterol Absorption Inhibitor, NPC1L1Reliable signal
NCT00092586: Percent change in LDL-C: ezetimibe+statin -25.8% vs placebo+statin -2.7%; treatment difference -23.1 percentage points (P<.001)
NCT03867318: Proportion achieving LDL-C goal <=100 mg/dL at Week 14: 22% (ezetimibe 10mg + atorvastatin, n=305) vs 7% (atorvastatin dose-titration alone, n=316); P<.01
Fimasartan / Atorvastatin / Ezetimibe (BR1017)Phase 3Small moleculeAT1 receptor; NPC1L1; HMG-CoA reductasePartial signal
NCT05930028: Week 8 co-primary endpoints (full analysis set, 148 randomized): mean sitting systolic BP, fimasartan + atorvastatin/ezetimibe vs atorvastatin/ezetimibe, LS mean difference -7.26 mm Hg (95% CI -12.91 to -1.61), P = 0.0124; LDL-C percent change, fimasartan + atorvastatin/ezetimibe vs fimasartan, LS mean difference -58.02% (95% CI -66.03 to -50.02), P < 0.0001 (Hong et al., Clin Ther 2025).
HyzetimibePhase 3Small moleculeNPC1L1Partial signal
NCT03433196: LDL-C percent change from baseline (primary endpoint, week 12): -16.39% (95% CI -19.04 to -13.74) with hyzetimibe (HS-25, referred to in this paper as hybutimibe) + atorvastatin vs -6.75% (95% CI -9.48 to -4.02) with atorvastatin alone, P<0.0001
NCT03413462: 第12周试验组LDL-C较基线的变化率为(-10.23±13.58)%,显著优于对照组(4.34±15.88)%。
Inclisiran (Leqvio)Phase 3RNA / oligonucleotidePCSK9Partial signal
NCT04652726: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -27.14% (95% CI -32.04 to -22.24) vs Part 1 - Placebo 1.4% (95% CI -3.97 to 6.78)
NCT04659863: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -21.6% (Standard Deviation 13.36) vs Part 1 - Placebo 11.7% (Standard Deviation 30.52)
LaroprovstatPhase 3Small moleculePCSK9Reliable signal
NCT06173570: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): AZD0780 1 mg -31.19% (95% CI -37.06--25.32) vs AZD0780 3 mg -33.83% (95% CI -39.78--27.88) vs AZD0780 10 mg -41.09% (95% CI -46.92--35.25) vs AZD0780 30 mg -46.62% (95% CI -52.48--40.76) vs Placebo 4.08% (95% CI -1.84-10.00); p=< 0.001 (AZD0780 1 mg vs Placebo), p=< 0.001 (AZD0780 3 mg vs Placebo), p=< 0.001 (AZD0780 10 mg vs Placebo), p=< 0.001 (AZD0780 30 mg vs Placebo)
Laroprovstat / RosuvastatinPhase 3Small moleculePCSK9 (laroprovstat component) + HMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
LepodisiranPhase 3RNA / oligonucleotideLPA gene / apolipoprotein(a) mRNAPartial signal
NCT05565742: Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180 (Baseline, Days 60 - 180): 16 mg LY3819469 -39.0% ± 7.37 vs 96 mg LY3819469 -74.4% ± 2.16 vs 400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) -93.7% ± 0.38 vs Placebo 3.1% ± 8.99; p=<0.001 (16 mg LY3819469 vs Placebo), p=<0.001 (96 mg LY3819469 vs Placebo), p=<0.001 (400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) vs Placebo)
Lerodalcibep (Lerochol)Phase 3Protein / enzyme therapeuticPCSK9Reliable signal
NCT04797104: LDL-C at Week 24: placebo-adjusted reduction of 58.61% (P<.0001); co-primary endpoint, mean of Weeks 22 and 24: placebo-adjusted reduction of 65.0% (P<.0001)
NCT05004675: LDL-C change from baseline at Day 270 (mITT): -53% with lerodalcibep vs -45.3% with inclisiran (P=0.0319); per-protocol: -55.4% vs -45.4% (P=0.005)
Maridebart Cafraglutide (MariTide)Phase 3PeptideGLP-1R agonist; GIPR antagonistnot yet gradedNo reviewed efficacy summary in this indication
MuvalaplinPhase 3Small moleculeApolipoprotein(a) [apo(a)] kringle domain / apo(a)-apoB100 interactionPartial signal
NCT05563246: Percent Change From Baseline in Lp(a) - Assessed Via Intact Lp(a) Assay (Baseline, Week 12): 10 mg LY3473329 -47.35% ± 4.811 vs 60 mg LY3473329 -81.57% ± 1.230 vs 240 mg LY3473329 -85.71% ± 0.927 vs Placebo 0.48% ± 6.382; p=<.001 (10 mg LY3473329 vs Placebo), p=<.001 (60 mg LY3473329 vs Placebo), p=<.001 (240 mg LY3473329 vs Placebo)
NL003Phase 3Gene therapy / editingHepatocyte growth factor (HGF)not yet gradedNo reviewed efficacy summary in this indication
ObicetrapibPhase 3Small moleculeCETPPartial signal
NCT05142722: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Obicetrapib 10mg -29.94% (Standard Error 1.104) vs Placebo 2.7% (Standard Error 1.571)
NCT05425745: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days): Obicetrapib 10 mg -36.05% (Standard Error 1.769) vs Placebo 0.25% (Standard Error 2.48)
Obicetrapib / Ezetimibe (Evlarco)Phase 3Small moleculeCETP, NPC1L1Partial signal
NCT06005597: Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C (84 Days): Fixed Dose Combination -45.58% (Standard Error 3.465) vs Placebo 3.03% (Standard Error 3.564)
OlpasiranPhase 3RNA / oligonucleotideLPA gene / apolipoprotein(a) mRNAPartial signal
NCT04270760: Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36 (Baseline and Week 36): Group 1: Olpasiran 10 mg Q12W -66.91% ± 1.78 vs Group 2: Olpasiran 75 mg Q12W -93.78% ± 1.78 vs Group 3: Olpasiran 225 mg Q12W -97.53% ± 1.82 vs Group 4: Olpasiran 225 mg Q24W -96.89% ± 1.85 vs Group 5: Placebo Q12W 3.60% ± 1.89; p=<0.001 (Group 1: Olpasiran 10 mg Q12W vs Group 5: Placebo Q12W), p=<0.001 (Group 2: Olpasiran 75 mg Q12W vs Group 5: Placebo Q12W), p=<0.001 (Group 3: Olpasiran 225 mg Q12W vs Group 5: Placebo Q12W), p=< 0.001 (Group 4: Olpasiran 225 mg Q24W vs Group 5: Placebo Q12W)
Ongericimab (Junshida)Phase 3Monoclonal antibodyPCSK9Reliable signal
NCT05325203: Percent change in LDL-C from baseline to week 24 (JS002-005/NCT05325203, HeFH, 135 patients): ongericimab 150mg Q2W -69.4% vs placebo (p<0.0001); ongericimab 450mg Q4W -80.6% vs placebo (p<0.0001)
NCT04781114: LDL-C percentage change from baseline to week 24 vs placebo: 150 mg Q2W -67.7% (95% CI -72.5% to -63.0%; P<0.0001); 300 mg Q4W -61.2% (95% CI -67.1% to -55.2%; P<0.0001).
Orforglipron (Foundayo)Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
PelacarsenPhase 3RNA / oligonucleotideApolipoprotein(a) mRNAPartial signal
NCT05305664: Rate of Lipoprotein Apheresis Sessions Performed Over 52 Weeks Normalized to the Weekly Lipoprotein Apheresis Schedule (Up to Week 52): Pelacarsen (TQJ230) 0.16 Apheresis sessions received per week (IQR 0.04 to 0.25) vs Placebo 0.93 Apheresis sessions received per week (IQR 0.9 to 1)
Pemafibrate (Parmodia)Phase 3Small moleculePPAR-alphaPartial signalNo reviewed efficacy summary in this indication
PMR (cilostazol ER)Phase 3Small moleculePhosphodiesterase 3 (PDE3)Weak signalNo reviewed efficacy summary in this indication
PravafenixPhase 3Small moleculeHMG-CoA reductase / PPAR-alphaPartial signalNo reviewed efficacy summary in this indication
QLC7401Phase 3RNA / oligonucleotidePCSK9not yet gradedNo reviewed efficacy summary in this indication
RanolazinePhase 3Small moleculeCardiac late sodium current (late INa, Nav1.5)Partial signal
NCT00099788: The primary end point occurred in 696 patients (21.8%) in the ranolazine group and 753 patients (23.5%) in the placebo group (hazard ratio 0.92). missed
NCT01562041: Change From Baseline in Maximum ST Segment Change Adjusted for Heart Rate (ST-HR) Index (Baseline up to Day 15): Ranolazine 500 mg — Test 1: 3.211 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.6553); Test 2: 2.822 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.0289); Test 3: 3.228 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.891); Test 4: 2.502 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.8884); Change From Baseline in Maximum ST/Heart Rate Index: -0.605 microvolts/beats per minute (microV/bpm) (Standard Deviation 1.0482)
RecaticimabPhase 3Monoclonal antibodyPCSK9Reliable signal
NCT04844125: Change in LDL-C from baseline at Week 12: -54.4% recaticimab vs -4.5% placebo; treatment difference -49.8 percentage points (95% CI -55.8 to -43.9), P<0.0001
NCT04849000: LDL-C reduction vs placebo at the primary endpoint timepoint: 150 mg Q4W -49.6% (95% CI 44.2-54.9%); 300 mg Q8W -52.8% (95% CI 48.3-57.2%); 450 mg Q12W -45.0% (95% CI 41.0-49.0%); P<0.0001 for all comparisons.
RetatrutidePhase 3PeptideGLP-1/GIP/glucagon receptor (triple)not yet gradedNo reviewed efficacy summary in this indication
RibupatidePhase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
SAL003Phase 3Monoclonal antibodyPCSK9Partial signalNo reviewed efficacy summary in this indication
Sarpogrelate (Anplag)Phase 3Small moleculeSerotonin 5-HT2A receptor (antagonist / inverse agonist)not yet gradedNo reviewed efficacy summary in this indication
SumecigrelPhase 3Small moleculeP2Y12 platelet receptorPartial signal
NCT03599284: Primary, inhibition of ADP-induced platelet aggregation (%IPA) at day 28: vicagrel 20/5 mg 30.19%, 24/6 mg 35.02%, 30/7.5 mg 45.61%, clopidogrel 32.55%; the paper reports these as comparable across all groups (P=0.0694) and sets no non-inferiority margin.
SYH2053Phase 3RNA / oligonucleotidePCSK9Partial signalNo reviewed efficacy summary in this indication
Tafolecimab (Sintbilo)Phase 3Monoclonal antibodyPCSK9Reliable signal
NCT04289285: LDL-C percent change from baseline to week 48, treatment difference vs placebo: -65.0% (97.5% CI: -70.2%, -59.9%) for tafolecimab 450 mg Q4W; -57.3% (97.5% CI: -64.0%, -50.7%) for 600 mg Q6W; both P < 0.0001
NCT04709536: Percent change in LDL-C from baseline to Week 12: tafolecimab -68.9% (SE 1.4%) vs placebo -5.8% (SE 1.8%); treatment difference -63.0% (95% CI -66.5% to -59.6%, P<0.0001)
ZiltivekimabPhase 3Monoclonal antibodyInterleukin-6Partial signal
NCT05021835: 3-point MACE (CV death, non-fatal MI, non-fatal stroke): HR 0.99 (95% CI 0.88-1.11) for ziltivekimab vs placebo. missed
NeovasculgenPhase 2/3Gene therapy / editingVEGF165 gene therapy (angiogenic plasmid)Partial signal
NCT03068585: Pain-free walking distance increased in the pCMV-vegf165 (Neovasculgen) treatment group by 110.4% at 6 months, versus no positive results in the standard-treatment control group
ABP-745Phase 2Small moleculeNLRP3 inflammasomenot yet gradedNo reviewed efficacy summary in this indication
ACP-01Phase 2Biologic (subtype unspecified)Autologous angiogenic cell precursor (ACP) therapyPartial signal
NCT02551679: Primary composite (de-novo gangrene, doubling of wound size, major amputation or death within 1 year): 12 of 46 participants on ACP-01 vs 3 of 21 on placebo, hazard ratio 2.046 (95% CI 0.577 to 7.255), p=0.258 (CT.gov posted results). missed
APACPhase 2PeptideVascular injury site glycocalyx / coagulation cascadenot yet gradedNo reviewed efficacy summary in this indication

Large race: only the 61 furthest-along competitors are listed; 62 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(23 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Brilinta (Ticagrelor) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 4Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2026-12-31 · NCT04937699 · CT.gov ↗
What to watch
Phase 4Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2026-12-31 · NCT06228456 · CT.gov ↗
What to watch
2027 (11)
January 2027 (3)
Phase 3Chronic Coronary DiseaseRecruiting
Est. primary completion 2027-01 · NCT05997693 · CT.gov ↗
What to watch
Phase 4Acute Myocardial InfarctionRecruiting
Est. primary completion 2027-01-15 · NCT04755387 · CT.gov ↗
What to watch
Phase 3Intracranial Arteriosclerosis, StrokeActive not recruiting
Est. primary completion 2027-01-31 · NCT05047172 · CT.gov ↗
What to watch
February 2027 (1)
Early phase / not applicableAtherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2027-02-20 · NCT06981390 · CT.gov ↗
What to watch
March 2027 (1)
Phase 1Healthy VolunteerNot yet recruiting
Est. primary completion 2027-03-31 · NCT07438886 · CT.gov ↗
What to watch
April 2027 (1)
Early phase / not applicableAtherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2027-04-29 · NCT07613840 · CT.gov ↗
What to watch
June 2027 (2)
Phase 3Acute Ischemic StrokeRecruiting
Est. primary completion 2027-06-30 · NCT06853535 · CT.gov ↗
What to watch
Phase 4Severe Aortic Valve Stenosis, Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement (TAVR) …Recruiting
Est. primary completion 2027-06-30 · NCT05283356 · CT.gov ↗
What to watch
August 2027 (1)
Early phase / not applicableAtherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2027-08 · NCT06714526 · CT.gov ↗
What to watch
September 2027 (1)
Phase 3Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2027-09-01 · NCT05476991 · CT.gov ↗
What to watch
December 2027 (1)
Phase 4Atherosclerotic Cardiovascular DiseaseNot yet recruiting
Est. primary completion 2027-12 · NCT07080684 · CT.gov ↗
What to watch
2028 (2)
April 2028 (1)
Phase 3Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2028-04 · NCT07582835 · CT.gov ↗
What to watch
December 2028 (1)
Phase 4Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2028-12-31 · NCT06451198 · CT.gov ↗
What to watch
2029 (3)
February 2029 (1)
Phase 4Ischemic Stroke, Symptomatic Intracranial Atherosclerotic StenosisRecruiting
Est. primary completion 2029-02-28 · NCT07932639 · CT.gov ↗
What to watch
July 2029 (1)
Phase 4Myocardial Infarction (MI)Recruiting
Est. primary completion 2029-07 · NCT07507500 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia, Endovascular ProcedureNot yet recruiting
Est. primary completion 2029-12-14 · NCT07821008 · CT.gov ↗
What to watch
2030 (4)
January 2030 (1)
Phase 3NSTEMI - Non-ST Segment Elevation MI, STEMI (ST Elevation MI), Myocardial InfarctionRecruiting
Est. primary completion 2030-01-01 · NCT07257198 · CT.gov ↗
What to watch
March 2030 (1)
Early phase / not applicableCardiac SurgeryNot yet recruiting
Est. primary completion 2030-03 · NCT07822620 · CT.gov ↗
What to watch
December 2030 (2)
Phase 2Chronic Kidney Disease (CKD)Recruiting
Est. primary completion 2030-12 · NCT07911124 · CT.gov ↗
What to watch
Phase 2Acute Ischemic StrokeNot yet recruiting
Est. primary completion 2030-12-31 · NCT07844603 · CT.gov ↗
What to watch
2034 (1)
September 2034 (1)
Phase 3StrokeRecruiting
Est. primary completion 2034-09 · NCT06352632 · CT.gov ↗
What to watch

See the full readout calendar ↗